Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

@article{Geddes2003RelapsePW,
  title={Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review},
  author={John R. Geddes and Stuart M Carney and Christina Davies and Toshiaki Furukawa and David J. Kupfer and Ellen Frank and Guy M. Goodwin},
  journal={The Lancet},
  year={2003},
  volume={361},
  pages={653-661}
}
BACKGROUND Antidepressant drugs can promote remission from acute depressive episodes. [...] Key Method Medline, Embase, Cinahl, PsycLIT, Psyndex, and Lilacs were searched. FINDINGS Data were pooled from 31 randomised trials (4410 participants). Continuing treatment with antidepressants reduced the odds of relapse by 70% (95% CI 62-78; 2p<0.00001) compared with treatment discontinuation. The average rate of relapse on placebo was 41% compared with 18% on active treatment. The treatment effect seemed to persist…Expand
Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders
TLDR
This meta-analysis emphasizes the importance of continuation treatment following acute response in depressive disorders, and the robust findings of relapse prevention designs contrast with acute antidepressant efficacy studies, and may be due to enrichment of the patient population. Expand
Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials.
TLDR
There is evidence, however, that with increasing number of episodes, patients develop a relative resistance against the prophylactic properties of antidepressant medication, regardless of a number of clinical and pharmacologic factors. Expand
Long-Term Treatment of Depression with Antidepressants: A Systematic Narrative Review
Objective: To examine the available scientific evidence for answers to clinically relevant questions on the effectiveness and tolerability of antidepressant drugs (ADs) for the long-term treatment ofExpand
Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.
TLDR
The trial data do not suggest that switching is a common early complication of treatment with antidepressants, and it may be prudent to use a selective serotonin reuptake inhibitor or a monoamine oxidase inhibitor rather than a tricyclic antidepressant as first-line treatment. Expand
Duration of Initial Antidepressant Treatment and Subsequent Relapse of Major Depression
TLDR
Discontinuation of antidepressant treatment for major depressive episodes at times less than 6 months was associated with rising risks after randomization to continuation with placebo, and this relationship requires critical consideration in both clinical management of depressed patients and the design and interpretation of treatment discontinuation trials. Expand
Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials
TLDR
Despite evidence of the efficacy of drug treatment compared to placebos or other controls, the findings further underscore the substantial, unresolved morbidity in treated MDD patients and strongly encourage further evaluations of specific, improved individual and combination therapies conducted over longer times. Expand
Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive Disorder
TLDR
Cutting the antidepressant dose following partial or full symptom improvement is associated with an increased risk of relapse in MDD. Expand
Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis.
TLDR
This meta-analysis underscores the importance of continuation treatment following acute response in all 5 anxiety disorders, however the relative efficacy of continuation antidepressant treatment appears to vary by disorder. Expand
Managing Antidepressant Discontinuation: A Systematic Review
TLDR
Cognitive behavioral therapy or mindfulness-based cognitive therapy can help patients discontinue antidepressants without increasing the risk of relapse/recurrence, but are resource intensive. Expand
Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents.
TLDR
There is little evidence to conclude which type of treatment approach is most effective in preventing relapse or recurrence of depressive episodes in children and adolescents, and the designs implemented in trials was diverse, which limits the generalisability of the results. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Discontinuing Antidepressant Treatment in Major Depression
TLDR
Compared with patients whose antidepressants were discontinued, those with continued treatment showed much lower relapse rates, and differences in relapses off versus on antidepressants fell markedly with longer follow‐up, but gradual discontinuation (dose‐tapering or use of long‐acting agents) did not yield lower relapse rate. Expand
Maintenance therapy for chronic depression. A controlled clinical trial of desipramine.
TLDR
Long-term maintenance treatment with desipramine appeared to be effective in the prevention or postponement of relapse of depression in patients who responded to desipramsine during the acute and continuation phases. Expand
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
TLDR
Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients. Expand
Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo‐controlled 6 month study
TLDR
The hypothesis that full dose continuation treatment is more effective than placebo in preventing relapse of depression is supported, and is in general agreement with those of other studies on antidepressants. Expand
Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
TLDR
Citalopram (20, 40 and 60 mg) is effective in the prevention of depressive recurrences and patients at risk should continue maintenance treatment at the dose necessary to resolve symptoms in the acute treatment phase. Expand
Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years.
TLDR
In geriatric patients with recurrent major depression, maintenance treatment with nortriptyline or IPT is superior to placebo in preventing or delaying recurrence and combined treatment using both appears to be the optimal clinical strategy in preserving recovery. Expand
Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
TLDR
Paroxetine was effective in preventing the reappearance of depression following an acute illness and the benefit of long-term pharmacotherapy for treating depressive illness is confirmed. Expand
Five-year outcome for maintenance therapies in recurrent depression.
TLDR
It is concluded that active imipramine treatment is an effective means of preventing recurrence beyond 3 years and that patients with previous episodes less than 2 1/2 years apart, therefore, merit continued prophylaxis for at least 5 years. Expand
Efficacy of Citalopram in the prevention of recurrent depression in elderly patients: Placebo-controlled study of maintenance therapy
TLDR
Long-term treatment with citalopram is effective in preventing recurrence of depression in the elderly and is well tolerated. Expand
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
TLDR
Relapse rates were lower among the patients who continued to take fluoxetine compared with those transferred to placebo in both the first interval, after 24 total weeks of treatment, and the second, after 38 total weeks, which were not significantly different between the groups. Expand
...
1
2
3
4
5
...